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and Raju Subramanian1
1Pharmacokinetics and Drug Metabolism, Amgen Inc., Thousand Oaks, California, USA; 2Clinical Pharmacology Modeling
and Simulations, Amgen Inc., Thousand Oaks, California, USA; and 3Global Development, Amgen Inc., Thousand Oaks,
California, USAIntroduction: Etelcalcetide, a novel calcimimetic agonist of the calcium-sensing receptor for treatment of
secondary hyperparathyroidism in chronic kidney disease patients on hemodialysis, is a D-amino acid
linear heptapeptide with a D-cysteine that is linked to an L-cysteine by a disulﬁde bond. In addition to
binding to the calcium-sensing receptor, etelcalcetide is biotransformed by disulﬁde exchange in whole
blood to predominantly form a covalent serum albumin peptide conjugate (SAPC). Key factors anticipated
to affect the pharmacokinetics and disposition of etelcalcetide in chronic kidney disease patients on he-
modialysis are the drug’s intrinsic dialytic properties and biotransformation kinetics.
Methods: These factors were investigated using in vitromethods, and the ﬁndings were modeled to derive
corresponding kinetic rate constants.
Results: Biotransformation was reversible after incubation of etelcalcetide or SAPC in human whole blood.
The rate of SAPC formation from etelcalcetide was 18-fold faster than the reverse process. Clearance of
etelcalcetide by hemodialysis was rapid in the absence of blood and when hemodialysis was initiated
immediately after addition of etelcalcetide to blood. Preincubation of etelcalcetide in blood for 3 hours
before hemodialysis resulted in formation of SAPC and decreased its clearance due to the slow rate of
etelcalcetide formation from SAPC. Etelcalcetide hemodialysis clearance was >16-fold faster than its
biotransformation.
Discussion: These results indicate that etelcalcetide should be administered after hemodialysis to avoid
elimination of a signiﬁcant fraction of the dose.
KI Reports (2016) 1, 24–33; http://dx.doi.org/10.1016/j.ekir.2016.04.002
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agonist
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).E telcalcetide (AMG 416, Figure 1) is a novel 8–aminoacid peptide calcimimetic intended for treatment
of secondary hyperparathyroidism in patients with
chronic kidney disease (CKD) receiving hemodialysis
treatment.1–4 Secondary hyperparathyroidism is a
disorder in which the impairment of calcium, phos-
phate, and vitamin D homeostasis leads to excessive
parathyroid hormone levels.5 Etelcalcetide covalently
binds to and activates the calcium-sensing receptor
of chief cells, thereby reducing parathyroid hormone
secretion from the parathyroid gland.4,6 In clinicalspondence: Raju Subramanian, Amgen Inc., One Amgen
r Drive, Thousand Oaks, California 91320, USA. E-mail:
amgen.com
ved 22 March 2016; revised 3 April 2016; accepted 8 April
published online 21 April 2016studies, etelcalcetide resulted in rapid, sustained,
dose-dependent reductions in serum parathyroid
hormone.1,2
Etelcalcetide is administered i.v. into the venous line
of the hemodialysis blood circuit at the end of a dialysis
session. After dose administration, etelcalcetide forms
multiple products (Figure 1). Etelcalcetide is bio-
transformed in whole blood by disulﬁde exchange of
the L-cysteine with other endogenous plasma thiols.7 A
dynamic equilibrium between etelcalcetide and its
biotransformation products is expected because of the
reversible nature of the disulﬁde exchange reactions.8
The major biotransformation product formed in blood
is a serum albumin peptide conjugate (SAPC) with a
high molecular weight (67,365 Da) that is formed by
covalent conjugation via the D-cysteine of etelcalcetide
to the cysteine at amino acid 34 of human serumKidney International Reports (2016) 1, 24–33
Figure 1. Biotransformation of etelcalcetide in whole blood. Products observed in plasma proﬁling are shown below; tris(2-carboxyethyl)
phosphine (TCEP) reduction of plasma results in formation of total M11. The backbone remains intact in all biotransformation products. R-group
moieties for etelcalcetide and biotransformation products are shown in the table. *Lower-case letters in “carrrar” represent D-amino
acids.
KZ Edson et al.: Etelcalcetide Biotransformation and Hemodialysis TRANSLATIONAL RESEARCHalbumin.7 Minor biotransformation products of low
molecular weight (<2000 Da) are formed with other
plasma thiols such as L-glutathione and L-cysteinyl-
glycine.7
Etelcalcetide is primarily eliminated by excretion in
urine in healthy humans and rats with normal kidney
function.2,7 In CKD patients on maintenance hemodi-
alysis who have little or no residual kidney function,
etelcalcetide is expected to be eliminated by hemodi-
alysis. Modern high-ﬂux clinical hemodialyzers remove
small molecules such as urea (60 Da) and creatinine
(113 Da) along with relatively small proteins (also called
middle molecules) such as b2-microglobulin (11,900
Da), whereas larger proteins, such as serum albumin
(w66,500 Da), are retained.9,10 Accordingly, dialysis is
expected to result in the removal of the low–molecular
weight biotransformation products of etelcalcetide,
whereas SAPC would be retained because of its high
molecular weight.
Published information about the pharmacokinetics
and disposition of a small synthetic peptide, such as
etelcalcetide, during hemodialysis is limited. Available
evidence shows that the intrinsic dialytic properties of
etelcalcetide and its biotransformation kinetics are
likely to be the key determinants of etelcalcetide
pharmacokinetics in CKD patients on hemodialysis. The
objective of this study was to characterize these de-
terminants using in vitro methods and model the
resultant data to derive the kinetic rate constants of
etelcalcetide dialysis and biotransformation. The ﬁnd-
ings were then useful to inform the timing of clinical
dose administration.Kidney International Reports (2016) 1, 24–33MATERIALS AND METHODS
This section contains the key study methods. Full
study methods including materials and bioanalysis are
provided in the Supplementary Methods online.
Whole-Blood Incubations With Etelcalcetide and
SAPC
Pooled whole blood from healthy volunteers (n ¼ 3) or
bovine blood was incubated in duplicate with either
[14C]etelcalcetide (10 mM, 0.3 mCi/ml), cold etelcalcetide
(5 mM), or SAPC (2.5 mM) for up to 6 hours at 37 C.
Blood was centrifuged, and the resultant plasma was
acidiﬁed with formic acid (1% vol/vol).
In Vitro Hemodialysis
The in vitro hemodialysis experimental setup is
depicted in Figure 2. In vitro hemodialysis experi-
ments were performed under 3 experimental condi-
tions using an Optiﬂux dialyzer.10 Peristaltic pump 1
moved the ﬂuid (either dialysate or bovine blood; 0.5
liters) in reservoir A at 50 ml/min (QB) through the
hemodialysis blood line tubing to the hollow ﬁber
capillaries of the dialyzer. Peristaltic pump 2 moved
dialysate (5 liters) from reservoir B at 250 ml/min (QD)
to the dialyzer extracapillary space. The dialysate
ﬂuid in reservoir B was mixed with a magnetic stir
bar, and the entire setup was maintained at ambient
temperature (w22 C).
Condition 1 assessed the intrinsic ability of etel-
calcetide to cross the dialyzer membrane and deter-
mined whether it adhered to the dialyzer apparatus.
No whole blood was used in this experiment.25
Figure 2. In vitro hemodialysis experimental setup. The dialyzer was
operated in a closed-circuit loop. Reservoir A, also referred to as the
“blood compartment,” contained 0.5 liters of either dialysate (for
condition 1) or whole blood (for conditions 2 and 3), and the reservoir
fluid was pumped by peristaltic pump 1 through the capillary bundle
in the dialyzer at 50 ml/min (QB). Reservoir B, also referred to as the
“dialysate compartment,” contained 5 liters of dialysate (in all ex-
periments) that was pumped in a countercurrent direction by peri-
staltic pump 2 through the extracapillary space in the dialyzer at 250
ml/min (QD). PM, pressure monitor.
TRANSLATIONAL RESEARCH KZ Edson et al.: Etelcalcetide Biotransformation and Hemodialysis[14C]Etelcalcetide and positive controls were added to
reservoir A, and the pumps were started immediately.
The spiked [14C]etelcalcetide dose was 1.1 mmol
(3.15 mCi), resulting in a concentration of 2.1 mM (2.2
mg/ml). At each time point, aliquots were withdrawn
from reservoirs A and B for radiometric analysis and
measurement of etelcalcetide, urea, creatinine, and
vitamin B12. Samples for etelcalcetide measurement
were acidiﬁed with formic acid (1% vol/vol). After
the 2-hour hemodialysis procedure, the ﬂuid in the
dialyzer was drained, and then reservoir A was
replaced with a bottle containing Solvable (Perki-
nElmer, Waltham, MA) (0.2 liters) to solubilize any
etelcalcetide-related material nonspeciﬁcally bound to
the dialyzer membrane. Solvable was circulated at
50 ml/min for 20 minutes, and samples were collected
for radiometric analysis.
Condition 2 emulated starting hemodialysis imme-
diately after etelcalcetide dosing in the clinic. Bovine
whole blood (0.5 liters) was warmed to 37 C.
[14C]Etelcalcetide was added and hemodialysis was
started immediately. Sodium heparin (100 U) was
spiked into the blood every 30 minutes. Positive
controls were added to reservoir A. The spiked [14C]
etelcalcetide dose was the same as condition 1. At
each time point, aliquots were withdrawn from
reservoirs A and B for radiometric analysis and26measurement of etelcalcetide, urea, creatinine, and
vitamin B12. A Solvable washout procedure was per-
formed similar to condition 1.
Condition 3 emulated starting hemodialysis after
etelcalcetide had sufﬁcient time to form biotransforma-
tion products (Figure 1) and establish equilibrium with
blood components. After [14C]etelcalcetide addition, the
blood was incubated for 3 hours at 37 C before hemo-
dialysis. Heparin (100 U) was added every hour. The
spiked [14C]etelcalcetide dose was 0.11 mmol (3.15 mCi),
resulting in a blood concentration of 0.21 mM (0.22
mg/ml). Heparin addition and blood and dialysate
sampling were the same as in condition 2. A Solvable
washout procedurewasperformed similar to condition 1.
Kinetic Modeling
Model 1 was developed using ADAPT 5 software11
(University of Southern California, Los Angeles, CA)
to simultaneously ﬁt the concentration data obtained
from the etelcalcetide and SAPC biotransformation ki-
netics experiments in human whole blood. Maximum
likelihood with additive, proportional, or both additive
and proportional error model12 was implemented. The
differential equations and details are in the
Supplementary Methods.
Model 2 was developed using Phoenix 64, version
1.4 (Certara, Princeton, NJ), and was an extension of
model 1 to ﬁt the etelcalcetide kinetic data from the
closed-loop in vitro hemodialysis experiments. The
differential equations and details are provided in the
Supplementary Methods.
RESULTS
In Vitro Biotransformation Proﬁle
[14C]Etelcalcetide biotransformation proﬁle in
human and bovine whole blood
Biotransformation of etelcalcetide was characterized
previously in vitro.7 Etelcalcetide was biotransformed
in human whole blood by disulﬁde exchange with
endogenous plasma thiols to form the disulﬁde pro-
ducts identiﬁed previously (Figure 1).7 The time
course of etelcalcetide disappearance and protein
conjugate formation was similar over 6 hours for
bovine and human blood (Supplementary Figure S1A).
The 14C proﬁles at each time point were also similar,
with etelcalcetide as the most abundant low–molecu-
lar weight (<2000 Da) component, M13 as the most
abundant low–molecular weight biotransformation
product, and protein conjugate as the most abundant
overall component (Supplementary Figure S2). The
protein conjugate in human plasma was previously
determined to be SAPC, which is formed by disulﬁde
exchange of the L-cysteine in etelcalcetide with the
reduced cysteine at amino acid position 34 in serumKidney International Reports (2016) 1, 24–33
KZ Edson et al.: Etelcalcetide Biotransformation and Hemodialysis TRANSLATIONAL RESEARCHalbumin.7 Cysteine 34 is preserved in bovine serum
albumin, and the protein conjugate formed in bovine
blood was thus inferred to be the bovine analogue of
SAPC. Based on the aforementioned results, bovine
blood was deemed an appropriate surrogate for hu-
man blood with respect to etelcalcetide biotransfor-
mation. Although [14C]etelcalcetide biotransformation
was slower at 25 C than at 37 C (Supplementary
Figure S1B), the same biotransformation products
were formed at the lower temperature, and their rates
of formation did not differ substantially.Figure 3. Formation of biotransformation products following etelcalcetide
whole blood. (a) Following duplicate incubation of etelcalcetide (5 mM) in
whole blood. Biotransformation products M10, M11, M12, and M13 are com
were quantiﬁed in duplicate at each time point.
Kidney International Reports (2016) 1, 24–33In Vitro Biotransformation Kinetics
Etelcalcetide Biotransformation in Human Whole Blood
The biotransformation kinetics of etelcalcetide
is shown in Figure 3a. Approximately 90% of etelcal-
cetide was biotransformed by 3 hours, and SAPC
accounted for w60% of etelcalcetide-related products,
as measured by tryptic peptide LC-MS/MS
(Supplementary Figure S3). M11, the sulfhydryl
(reduced) form of the D-amino acid peptide backbone in
etelcalcetide, was present in minor amounts in plasma
after etelcalcetide incubation in whole blood. M11and serum albumin peptide conjugate (SAPC) incubations in human
whole blood. (b) Following duplicate incubation of SAPC (2.5 mM) in
bined in a single line. Etelcalcetide and biotransformation products
27
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is referred to as “total M11” (Figure 1) because it rep-
resents all etelcalcetide-related material in plasma with
an intact D-amino acid backbone. An authentic stan-
dard of M13 was not available; thus, the quantitation
curve for M10 was used to estimate concentrations of
M13 in plasma. The sum total of monitored products at
1 and 6 hours was w90% and 77% of total M11,
respectively (Figure 3a).
SAPC Biotransformation in Human Whole Blood
SAPC also underwent disulﬁde exchange in human
whole blood to form etelcalcetide as the predominant
product (w3%) and M10 to M13 as minor products
(collectively 8%; Figure 3b). The conversion rate to thiol
exchange products was signiﬁcantly slower for SAPC
compared with etelcalcetide. Approximately 12% of
SAPCwas biotransformed, and a plateau was reached by
3 hours.Figure 4. Hemodialysis clearance of etelcalcetide. (a and b) Total C-14
dosed into a buffered aqueous solution (dialysate) in reservoir A. (c and
calcetide was dosed into bovine blood in reservoir A. (e and f) Total C-14
37 C after etelcalcetide was spiked into bovine blood in reservoir A. Etelc
each time point. Total C-14, total [14C]etelcalcetide-derived radioactivity; e
28In Vitro Hemodialysis
Condition 1: Hemodialysis of a Buffered Aqueous
Solution (Dialysate) Immediately After Addition of
Etelcalcetide
Recovery of total C-14, which represented the total
[14C]etelcalcetide-derived radioactivity, was quantita-
tive (114% of the spiked dose; Figure 4a). Etelcalcetide
concentration in reservoir A (“blood compartment”)
declined exponentially and appeared in reservoir B
(“dialysate compartment”) at a similar rate (Figure 4b).
Hemodialysis cleared approximately 70% of the dose in
the ﬁrst 15 minutes with almost all of it present as
intact etelcalcetide in the dialysate compartment. A
minor amount of the administered dose (3.3%) was
recovered in the Solvable washout, which was likely
due to small amounts of ﬂuids remaining in the appa-
ratus after it was drained. These results demonstrated
that the dialyzer readily cleared etelcalcetide. Also,
etelcalcetide did not bind to the dialyzer assembly.(a) and intact etelcalcetide (b) immediately after etelcalcetide was
d) Total C-14 (c) and intact etelcalcetide (d) immediately after etel-
(e) and intact etelcalcetide (f) after a 3-hour preincubation period at
alcetide and total C-14 were quantiﬁed from triplicate aliquots from
q., etelcalcetide equivalents.
Kidney International Reports (2016) 1, 24–33
Figure 5. Modeling of the kinetic proﬁles obtained following etelcalcetide and serum albumin peptide conjugate (SAPC) incubations in human
whole blood. (a) Model 1. (b) Observed versus model-predicted concentration-time curves. The differential equations and initial conditions are
described in Materials and Methods. BTx* represents the collective concentration of all etelcalcetide biotransformed products including M10 to
M13 but excluding SAPC. kb and kdb are rate constants for the disulfide exchange between etelcalcetide and BTx*. kc and kdc are the rate
constants for disulfide exchange between etelcalcetide and SAPC. Pooled whole blood from healthy volunteers was incubated in duplicate with
etelcalcetide or SAPC. Model 1 was fitted using measured concentrations of etelcalcetide and SAPC and the calculated concentration of BTx* in
whole blood, based on mean values of duplicate samples.
KZ Edson et al.: Etelcalcetide Biotransformation and Hemodialysis TRANSLATIONAL RESEARCHCondition 2: Hemodialysis of Bovine Whole Blood
Immediately After Addition of [14C]etelcalcetide
Figure 4c and d show the kinetic changes of total C-14 and
the intact etelcalcetide during hemodialysis performed
under condition 2. The spiked total C-14 in bovine whole
blood was dialyzed rapidly out of the blood compartment
and appeared in the dialysate compartment at a similar rate
(Figure 4c). As expected, intact etelcalcetide decreased
over the 2-hour hemodialysis period (Figure 4d). Based on
the biotransformation kinetics described above, the
decrease of etelcalcetide in this experiment was attributed
to exchange of L-cysteine with thiols in blood. The entire
spiked 14C dose (108%) was recovered in the blood and
dialysate after 2 hours, indicating that etelcalcetide-
related products did not bind signiﬁcantly to the dia-
lyzer assembly. In the ﬁrst 15 minutes of hemodialysis,
59% and 57% of the spiked radioactivity and intact
etelcalcetide, respectively, were dialyzed.Kidney International Reports (2016) 1, 24–33The drug in the blood compartment at time
0 appeared to be greater than the calculated [14C]etel-
calcetide dose. This was likely due to an experimental
limitation wherein [14C]etelcalcetide spiked in whole
blood could not be mixed completely before the ﬁrst
sample was obtained from reservoir A at time 0. The
hemodialysis experiment was performed at ambient
room temperature because it was not feasible to main-
tain the dialysis setup at a physiological temperature (37
C) for the duration of the 2-hour experiment; however,
the kinetics of etelcalcetide biotransformation is similar
at both temperatures (Supplementary Figure S1) because
it proceeds via a chemical disulﬁde exchange reaction.13
A minor amount of 14C (0.2% of the spiked dose)
was recovered during the washout period. Similar to
condition 1, this demonstrated that etelcalcetide did
not bind to the dialyzer assembly when blood was
present.29
Table 1. Rate constant estimates from the model ﬁtting of the
biotransformation kinetics and hemodialysis clearance data sets
Parameter Estimate SE (% CV)
Model 1: Etelcalcetide biotransformation kinetics
kc (min
–1) 0.007 6.65
kdc (min
–1) 0.00038 8.37
kb (min
–1) 0.00525 16.7
kdb (min
–1) 0.0025 32.5
Etelcalcetide proportional error 0.185 18.7
SAPC additive error (mM) 0.0175 70.4
SAPC proportional error 0.133 19.8
BTx* additive error (mM) 0.241 25.0
Model 2: Etelcalcetide hemodialysis kinetics
Condition 1
kAB (min
–1) 0.118 0.35
kBA (min
–1) 0.00932 0.52
EtelcalcetideResA proportional error 0.119 0.035
EtelcalcetideResB proportional error 33.8 0.52
Conditions 2 and 3
kAB (min
–1) 0.0718 22.2
kBA (min
–1) 0.0364 46.8
EtelcalcetideResA proportional error 0.446 10.1
EtelcalcetideResB proportional error 0.123 18.8
Model 1 was ﬁtted using measured concentrations of etelcalcetide and SAPC and the
calculated concentration of BTx* in whole blood, based on mean values of duplicate
samples. Model 2 was ﬁtted using measured amounts of etelcalcetide in reservoirs A and
B, based on mean values of triplicate samples.
CV, coefﬁcient of variation; SAPC, serum albumin peptide conjugate. kc and kdc are the
conjugation and deconjugation rate constants of etelcalcetide and SAPC. kb and kdb are
the conjugation and deconjugation rate constants of etelcalcetide and BTx*. BTx* rep-
resents the collective concentration of all etelcalcetide biotransformed products excluding
SAPC (see Materials and Methods for details). kAB and kBA are forward and reverse rate
constants of etelcalcetide hemodialysis clearance between reservoirs A and B. Etelcal-
cetideResA and etelcalcetideResB are etelcalcetide amounts in reservoirs A and B.
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After a 3-Hour Preincubation at 37 C With
[14C]etelcalcetide
Figure 4e and f show the kinetic changes in total C-14
and intact etelcalcetide during hemodialysis following
a 3-hour preincubation of etelcalcetide in bovine whole
blood at 37 C. As previously demonstrated (Figure 1),7
etelcalcetide underwent disulﬁde exchange with
endogenous thiols in blood. Low–molecular weight
disulﬁde exchange products (1000–2300 Da) were
readily dialyzed. However, the predominant product of
disulﬁde exchange was SAPC (67 kDa), which had a
signiﬁcantly higher molecular weight than the cutoff of
the dialyzer membrane. Consequently, the proportion
of the total C-14 eliminated from the blood compart-
ment with a 3-hour preincubation period (23% in 15
minutes) was attenuated compared with no pre-
incubation in condition 2 (59% in 15 minutes). Addi-
tionally, the proportion of the dose eliminated in 2
hours only reached 24% with preincubation versus
84% eliminated without preincubation.
Dialysis of Positive Controls: Urea, Creatinine, and
Vitamin B12
Positive controls (urea, creatinine, and vitamin B12)
were cleared from the blood compartment at similar
rates in conditions 1 and 2 (Supplementary
Figure S4). Estimated urea and creatinine clearance
in condition 1 was 50 and 47 ml/min, respectively,
which was the expected clearance for this dialyzer at
the operated ﬂow rate. This suggests that the in vitro
hemodialysis setup approximated clinical dialyzer
clearance for these solutes. Vitamin B12 was cleared
from the blood compartment at a rate similar to that
of creatinine and urea, as 44% and 8% of the dose
remained in bovine blood at 15 and 120 minutes,
respectively.
Modeling of Biotransformation and Hemodialysis
Kinetics
Biotransformation Kinetics Model
Time course data from etelcalcetide and SAPC in-
cubations in human whole blood were simultaneously
ﬁt with model 1 (Figure 5a) to derive rate constants for
disulﬁde exchange. Model prediction versus observed
data is displayed in Figure 5b, and rate parameter es-
timates are listed in Table 1. Model 1 described the
observed data well, with coefﬁcients of variance
<33% for each rate constant. The rate of disulﬁde
exchange from etelcalcetide to form SAPC was 18-fold
faster than the reverse process (kc vs. kdc). The rate of
disulﬁde exchange from etelcalcetide to BTx* (i.e.,
collective concentration of all etelcalcetide biotrans-
formed products including M10–M13 but excluding30SAPC) was 2.1-fold faster than the reverse process
(kb vs. kdb).
In Vitro Hemodialysis Model
The concentration-time data from in vitro hemodialysis
experiments under conditions 1, 2, and 3 were ﬁtted
simultaneously with model 2 (Figure 6a) using 1 set of
rate constants (Table 1). Model 2 described the observed
data well (Figure 6b and c), with coefﬁcients of
variance <50%. In the absence of blood (condition 1),
the rate constant for etelcalcetide decline in reservoir
A (kAB) was 0.118 min
–1, corresponding to hemodial-
ysis clearance of 59 ml/min. This value was close to
the theoretical maximum of 62.5 ml/min obtainable
under the ﬂow rates used in the experiment.14 The
clearance value was also higher than the ﬂow rate
from reservoir A, likely due to the convection
gradient in the hemodialysis setup. In the presence of
blood (conditions 2 and 3), kAB for etelcalcetide
decline in reservoir A was 0.0718 min–1, which cor-
responded to a hemodialysis clearance of 36 ml/min
(w70% of blood ﬂow rate).
DISCUSSION
Multiple factors are likely to affect the pharmacokinetics
and disposition of etelcalcetide in a clinical hemodialysisKidney International Reports (2016) 1, 24–33
Figure 6. Simultaneous modeling of the hemodialysis clearance proﬁles obtained following etelcalcetide incubation in bovine whole blood.
(a) Model 2. (b) Observed versus model-predicted concentration-time curves in condition 1. (c) Observed versus model-predicted concentration-
time curves in conditions 2 and 3. Conjugation and deconjugation rates (kc, kdc, kb, kdb) were fixed to the values obtained from model 1 fitting of
the in vitro biotransformation kinetics data. kAB and kBA are forward and reverse rate constants of etelcalcetide hemodialysis clearance be-
tween reservoirs A and B. BTx* represents the collective concentration of all etelcalcetide biotransformed products including M10 to M13 but
excluding serum albumin peptide conjugate (SAPC). Model 2 was fitted using measured amounts of etelcalcetide in reservoirs A and B, based
on mean values of triplicate samples.
KZ Edson et al.: Etelcalcetide Biotransformation and Hemodialysis TRANSLATIONAL RESEARCHsetting. These include the drug’s intrinsic dialytic
properties, biotransformation kinetics, non-covalent
plasma protein binding and blood-to-plasma partition
ratio, permeability, and the extent and rate of its dis-
tribution into and out of peripheral tissue compartments.
The non-covalent plasma protein binding, the blood-to-
plasma ratio, and permeability have been previously
reported.7 The rate of etelcalcetide distribution into pe-
ripheral tissue compartments has not been determined;
however, that was unlikely to affect this investigation
because of the drug’s very low permeability.
In this study, the dialytic properties and biotrans-
formation kinetics of etelcalcetide were investigated by
in vitro methods. The results of this investigation were
used to provide insights into the disposition of etel-
calcetide that would be difﬁcult to determine in aKidney International Reports (2016) 1, 24–33clinical setting. Etelcalcetide and its biotransformation
products did not bind to the polysulfone dialyzer,
which showed that the in vitro apparatus was free of
that potential confounding artifact. In the absence of
blood, as expected for a molecule of etelcalcetide’s
molecular weight, the dialyzer cleared etelcalcetide at a
rate that was near the theoretical maximum and was
similar to the clearance rates of the control solutes urea,
creatinine, and vitamin B12.
14
Etelcalcetide and its biotransformation products exist
in a dynamic equilibrium state. Consequently, as etel-
calcetide and its low–molecular weight biotransformation
products are removed by hemodialysis, they are reformed
from SAPC by re-equilibration. The overall removal of
etelcalcetide is therefore dependent on the proportion of
the drug present during dialysis in dialyzable and non-31
TRANSLATIONAL RESEARCH KZ Edson et al.: Etelcalcetide Biotransformation and Hemodialysisdialyzable forms and the rates at which these forms
interconvert. A rate of conversion from SAPC to etelcal-
cetide that is fast relative to etelcalcetide dialytic clear-
ance would result in rapid removal of total etelcalcetide.
A rate of conversion that is slow relative to dialytic
clearance would result in rapid removal of low–molecular
weight forms of the drug, and then additional removal
would occur at a rate determined by the rate of etelcal-
cetide formation from SAPC. SAPC does not cross the
dialyzer membrane, so the proportion of total etelcalce-
tide present in the form of SAPC can be eliminated
during dialysis only as rapidly as the conversion from
SAPC to etelcalcetide.
In this study, the etelcalcetide hemodialysis clear-
ance rate was shown to be >16-fold faster than its
conversion to SAPC, and the rate of conversion of
SAPC to etelcalcetide was far slower (w200-fold) than
the dialytic rate constant. Consequently, administra-
tion of etelcalcetide during or shortly before dialysis
would result in its rapid removal in the dialysate.
When etelcalcetide was preincubated in blood before
hemodialysis for a period of time sufﬁcient to reach
equilibrium with SAPC (preincubation for 3 hours
was tested in the experiments), the dialysis of all
etelcalcetide-related components as measured by total
radioactivity was slow. This ﬁnding is consistent
with rapid formation of SAPC and a slow rate of the
reverse process. The conversion of etelcalcetide to
SAPC was 18-fold faster than conversion of SAPC to
etelcalcetide, which is consistent with the ﬁnding
that SAPC was the predominant etelcalcetide-related
species in blood.7 This is also consistent with the
>7-day plasma half-life of etelcalcetide in CKD pa-
tients on hemodialysis.3,15 As previously established7
and reafﬁrmed, SAPC was the predominant
biotransformation product. Other low–molecular
weight products were minor compared with SAPC
and are therefore not likely to contribute signiﬁcantly
to the overall disposition or elimination of etelcalce-
tide during hemodialysis.
For drugs requiring i.v. dosing to hemodialysis pa-
tients, it is most convenient to administer the dose
during hemodialysis (commonly into the venous line of
the dialyzer). For example, erythropoietin (molecular
weight w34 kDa) can be dosed at any time during a
hemodialysis session because it has minimal passage
across a dialyzer membrane. In this in vitro investiga-
tion, it was demonstrated that introduction of etelcal-
cetide into the blood immediately before hemodialysis
resulted in rapid elimination. The elimination rate
constant of 0.0718 min–1 translated to a half-life
of approximately 10 minutes. In 1 hour of dialysis
(w6 half-lives), 98.5% of the drug would be cleared by32dialysis, because only a small amount of SAPC can be
formed under these conditions.
A drug’s non-covalent binding to plasma proteins
and its blood-to-plasma partition ratio affect hemodi-
alysis clearance.16 In bovine blood, etelcalcetide was
only 40% bound non-covalently to plasma proteins
(data not shown). This is consistent with the in vitro
ﬁnding that the elimination rate constant in blood was
60% of that in the absence of blood. Non-covalent
binding of etelcalcetide to plasma proteins in human
blood was also low (w50%).7 The etelcalcetide blood-
to-plasma ratio was close to the hematocrit value
(w0.5) and hence is not expected to appreciably affect
how much etelcalcetide in plasma is cleared during
hemodialysis.
In summary, the biotransformation process of etel-
calcetide and the inﬂuence of hemodialysis on etelcal-
cetide elimination are complex. The in vitro incubation
and hemodialysis models used here provided a practical
way to characterize etelcalcetide properties that would
otherwise be difﬁcult to study in clinical settings.
Based on the rate constant comparisons of biotrans-
formation and hemodialysis in vitro, etelcalcetide
would be signiﬁcantly eliminated if administered dur-
ing hemodialysis. The ﬁndings from this study support
dosing etelcalcetide immediately after hemodialysis in
CKD patients with secondary hyperparathyroidism, as
tested in clinical studies.1,3
DISCLOSURE
All authors are or were employed by and are shareholders
of Amgen, which is developing etelcalcetide for the
treatment of secondary hyperparathyroidism in chronic
kidney disease patients on maintenance hemodialysis.
Jonathan Latham of PharmaScribe LLC received ﬁnancial
support from Amgen to assist with preparation and
submission of the manuscript.
ACKNOWLEDGMENTS
Amgen provided ﬁnancial support for the conduct of the
research and preparation of the article. We thank Sean
Zhu for the biotransformation proﬁle methods and Joel
Esmay for measuring plasma protein binding; Professor
Larry Cowgill at University of Davis for previous explor-
atory analysis and consultation; Justin Murray for stable
label standards; Rob Milburn for SAPC synthesis; and
Nathan Teuscher at Certara and Theresa Yurasczek for
facilitating the modeling in Phoenix. Holly Tomlin
(Amgen Inc.) and Jonathan Latham (on behalf of Amgen
Inc.) supported the preparation and submission of the
manuscript. Divya Ganesan and Ninad Ranade (CACTUS
on behalf of Amgen Inc.) provided journal formatting and
editing support.Kidney International Reports (2016) 1, 24–33
KZ Edson et al.: Etelcalcetide Biotransformation and Hemodialysis TRANSLATIONAL RESEARCHSUPPLEMENTARY MATERIAL
Supplemental ﬁgures show the etelcalcetide biotrans-
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